GRAIL (NASDAQ:GRAL) Trading 7.6% Higher – Time to Buy?

GRAIL, Inc. (NASDAQ:GRAL) shot up 7.6% during trading on Monday . The stock traded as high as $75.75 and last traded at $74.7330. 225,291 shares were traded during trading, a decline of 76% from the average session volume of 934,800 shares. The stock had previously closed at $69.48.

Analyst Upgrades and Downgrades

GRAL has been the topic of a number of analyst reports. Mizuho lifted their price target on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Robert W. Baird set a $70.00 target price on shares of GRAIL in a report on Wednesday, May 6th. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. The Goldman Sachs Group began coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $67.78.

GRAIL Stock Performance

The firm has a 50 day moving average of $66.71 and a 200-day moving average of $66.29. The stock has a market capitalization of $3.30 billion, a PE ratio of -7.59 and a beta of 3.24.

GRAIL (NASDAQ:GRAL) last released its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating the consensus estimate of ($2.66) by $0.10. The company had revenue of $44.69 million for the quarter, compared to analysts’ expectations of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. On average, sell-side analysts predict that GRAIL, Inc. will post -10.93 earnings per share for the current year.

Insider Transactions at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the transaction, the insider directly owned 163,738 shares in the company, valued at $10,001,117.04. The trade was a 0.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.83% of the stock is currently owned by insiders.

Institutional Trading of GRAIL

A number of institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. increased its position in GRAIL by 154,361.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 91,132 shares of the company’s stock worth $7,531,000 after purchasing an additional 91,073 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of GRAIL by 9.0% during the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after buying an additional 163,790 shares during the last quarter. WIM INVESTMENT MANAGEMENT Ltd grew its stake in shares of GRAIL by 68.9% in the 4th quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 106,400 shares of the company’s stock valued at $9,107,000 after buying an additional 43,400 shares in the last quarter. Pictet Asset Management Holding SA increased its holdings in GRAIL by 1,036.8% in the fourth quarter. Pictet Asset Management Holding SA now owns 40,926 shares of the company’s stock worth $3,585,000 after buying an additional 37,326 shares during the last quarter. Finally, Profund Advisors LLC raised its position in GRAIL by 141.2% during the fourth quarter. Profund Advisors LLC now owns 22,776 shares of the company’s stock valued at $1,949,000 after acquiring an additional 13,334 shares in the last quarter.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.